Extraordinary general meeting installs Lars Rebien Sorensen as chair

Novo Nordisk A/S, the Danish maker of the semaglutide medicines Ozempic, Wegovy and Rybelsus, held an Extraordinary General Meeting on Friday 14 November 2025 at 14:00 CET for the sole purpose of electing new members to its Board of Directors ^[1]. Shareholders approved the slate backed by the company's controlling foundation, installing Lars Rebien Sorensen as chair.

Under the outcome of that vote, the shareholder-elected board is Sorensen as chair, Cees de Jong as vice chair, and Britt Meelby Jensen, Kasim Kutay and Stephan Engels as members, alongside four employee-elected directors who continue to serve. Novo Nordisk has published the minutes and voting results from the meeting, along with the meeting notice and the written questions it received from shareholders ahead of time, on its investor relations site ^[1].

The meeting was run in English with simultaneous interpretation into Danish, and shareholders were allowed to submit questions in Danish if they preferred ^[1]. Novo Nordisk says general meetings are called with three to five weeks' notice, and that shareholders "have the ultimate authority over the company" and exercise it at these meetings ^[1]. Registered shareholders could also vote by proxy or by correspondence on each agenda item, or ask questions in writing during the meeting through an online meeting application ^[1].

Some details that often matter in a contested board fight are not available in the sources reviewed here. The exact vote tallies for each candidate, the arguments made for and against the new slate, and any statements from the incoming chair about company strategy are contained in the meeting minutes and webcast rather than in the material available for this report ^[1]. A second news account of the vote could not be retrieved. So the size of the shareholder majority behind the change is not confirmed here.

Why it matters for patients

Board changes at a drugmaker do not alter a prescription, a dose, a label or a supply schedule by themselves. Approvals and labeling for semaglutide products in the United States are decided by the Food and Drug Administration, not by a company's board, and none of that changed on 14 November.

What a board does control is the people and priorities at the top: who runs the company, how much gets spent on manufacturing capacity and research, and how aggressively the company competes on price and new products. Novo Nordisk sells the GLP-1 medicines many American patients use for type 2 diabetes and obesity, and it is in a head-to-head market fight with tirzepatide (Mounjaro and Zepbound). Over months and years, decisions made by a new board can shape supply, pipeline bets and commercial strategy. Whether this board will change course on any of those fronts is not yet known; the sources available do not contain strategy commitments from the new directors ^[1].

In the near term, patients should expect the practical things that affect them most day to day — pharmacy stock, insurance coverage decisions, copay programs and cash-pay pricing — to be set by existing company policy and by insurers, not by the change in board membership. Nothing in the meeting materials published so far addresses US pricing or access programs ^[1].

What happens next

Novo Nordisk has posted the minutes and voting results from the 14 November meeting, plus English and Danish recordings of the webcast, for shareholders and the public to review ^[1]. The company's regular reporting cycle, including its annual report and financial calendar, remains the place where any resulting changes in strategy, spending or leadership would normally be disclosed ^[1]. No date has been announced in these materials for a strategy update from the new board.